after ex parte appeal
on 15 Apr 2024
Last Applicant/ Owned by
9880 Campus Point Drive, Suite 210
San Diego
CA
92121
Serial Number
90868359 filed on 05th Aug 2021
Registration Number
N/A
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
Clinical diagnostic instruments for medical use, namely, nucleic acid sequencers, imaging devices and analyzers for use in the field of genetic analysis Assays and reagents for use in genetic research; diagnostic reagents for scientific or research use; diagnostic reagents for clinical or medical laboratory use; reagents and reagent kits comprised primarily of nucleic acids, naturally occurring oRead More
Clinical diagnostic instruments for medical use, namely, nucleic acid sequencers, imaging devices and analyzers for use in the field of genetic analysis
Computer systems, namely, computer hardware, downloadable and recorded computer software and associated downloadable data files for collecting, storing, analyzing and reporting biological information, and for sample tracking and managing projects, laboratory workflow and data, all the foregoing for use in the fields of diagnostic and clinical research and for clinical diagnostic purposes; downloadable and recorded computer software for data collection, management, and analysis of genetic information for use in the fields of diagnostic and clinical research and for clinical diagnostic purposes; clinical diagnostic instruments for scientific use, namely, nucleic acid sequencers, imaging devices and analyzers; all of the foregoing for use in the field of genetic analysis
Medical diagnostic reagents; clinical medical diagnostic reagents; reagent kits and reagent beads with attached biomolecules, comprised primarily of oligonucleotides and other nucleic acids, natural and modified nucleotides, polypeptides, buffers, labels, and substrates, for clinical medical diagnostic purposes; reagents and reagent kits comprised primarily of nucleic acids, naturally occurring or modified nucleotides, enzymes, labels, and buffers, all for the purpose of preparing, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, regulation, transcription, and expression for diagnostic medical use and for clinical medical use; all of the foregoing for use in the field of genetic analysis
Assays and reagents for use in genetic research; diagnostic reagents for scientific or research use; diagnostic reagents for clinical or medical laboratory use; reagents and reagent kits comprised primarily of nucleic acids, naturally occurring or modified nucleotides, enzymes, labels, and buffers, all for the purpose of preparing, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, regulation, transcription, and expression in the fields of for scientific research use, for diagnostic scientific use, and for clinical laboratory research use; clinical diagnostic reagents for laboratory use; reagent kits and reagent beads with attached biomolecules, comprised primarily of oligonucleotides and other nucleic acids, natural and modified nucleotides, polypeptides, buffers, labels, and substrates, for clinical diagnostic laboratory purposes; all of the foregoing for use in the field of genetic analysis
No 90868359
No Service/Collective Mark
No ELEM-207
No
No
No
No
No
No
No
No
| Status Date | Action Taken |
|---|---|
| 18th Apr 2024 | ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL |
| 15th Apr 2024 | EXPARTE APPEAL TERMINATED |
| 15th Apr 2024 | ABANDONMENT - AFTER EX PARTE APPEAL |
| 30th Jan 2024 | EXPARTE APPEAL AFFIRMED/REVERSED IN PART |
| 12th Sep 2023 | REPLY BRIEF FILED - CHECK TTAB FILES |
| 24th Aug 2023 | EXAMINERS STATEMENT - COMPLETED |
| 24th Aug 2023 | EXAMINERS STATEMENT E-MAILED |
| 24th Aug 2023 | NOTIFICATION OF EXAMINERS STATEMENT E-MAILED |
| 28th Jun 2023 | JURISDICTION RESTORED TO EXAMINING ATTORNEY |
| 27th Apr 2023 | ACTION CONTINUING FINAL - COMPLETED |
